



Pharma Day with Japan Tobacco Pharmaceutical Division

The Pharmaceutical Division of Japan Tobacco Inc. (JT Pharma) is dedicated to healthcare through discovery and development of “First-in-Class” drugs which change the patient’s life for the better.

JT Pharma is focusing on cutting edge, innovative science and global development of orally active, small molecule therapeutics. In addition there is an increasing emphasis on in-licensing of clinical phase assets for development in Japan.

JT Pharma 1:1 Meeting Opportunity

JT Pharma is seeking partnering opportunities for early stage collaborative research based on validated drug targets, small chemical lead compounds, or disease-relevant cell assay systems. JT Pharma has also a strong interest in in-licensing opportunities of clinical phase assets and novel drug discovery technologies.

<Collaborative research at early research phases >

Diseases of interest: Type II Diabetes, Dyslipidemia, Non-alcoholic Steatohepatitis, HBV, Diabetic Complications, Chronic Heart Failure, Pulmonary Arterial Hypertension, Multiple Sclerosis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease, Sarcopenia / Cachexia, Chronic Kidney Disease, Systemic Scleroderma / Organ Fibrosis, Psychiatric / Neurological Disorders

Focus: Identification and development of First-in-Class, orally active small molecule therapeutics

<In-licensing of clinical phase assets>

Diseases of interest: Renal Diseases, Allergic Diseases, Dermatological Diseases

Focus: Development of small molecules, proteins, antibodies or nucleic acid as therapeutics in Japan (Small molecules are preferable)

<Drug discovery technologies >

Technologies related to: Discovery of new MOAs, Drug target prediction / identification / validation, Diseases-relevant cell culture systems, Drug screening using organoid culture, Hit and lead generation including biophysical techniques, Analysis techniques for high-content & phenotypic screening, SBDD / LBDD / de novo compound design, Cryo-EM, Prediction of compound synthesis route, Prediction of ADME / toxicity / physico-chemical properties / pharmacological activity of compounds, Human PK prediction, Modulation of RNA or protein synthesis, Modulation of cellular stress responses, CNS translational research, Omics research / bioinformatics

One on One Meetings will take place on October 30, 2018.

Application form : Next 2 Pages

Application Deadline: September 30, 2018

E-mail application to sakoda@akrospharma.com

One on One Meeting Application

* : mandatory

Name*	
Professional Title*	
Phone*	
Email*	

Company name*									
Address*									
Website									
Year of incorporation/ formation									
Number of employees									
Technology Classification*: <i>(select all that apply)</i>	<table style="width: 100%; border: none;"> <tr> <td>Medical Device</td> <td>Biotechnology</td> </tr> <tr> <td>Pharmaceutical</td> <td>Biomarker</td> </tr> <tr> <td>Diagnostic</td> <td>Software Platform</td> </tr> <tr> <td>Informatics</td> <td>Other:</td> </tr> </table>	Medical Device	Biotechnology	Pharmaceutical	Biomarker	Diagnostic	Software Platform	Informatics	Other:
Medical Device	Biotechnology								
Pharmaceutical	Biomarker								
Diagnostic	Software Platform								
Informatics	Other:								
Area of focus*: <i>(select all that apply)</i>	<table style="width: 100%; border: none;"> <tr> <td>Metabolic diseases</td> <td>inflammation/ immunity</td> </tr> <tr> <td>chronic viral infectious diseases</td> <td>CNS</td> </tr> <tr> <td>Renal diseases</td> <td>Dermatological diseases</td> </tr> <tr> <td>Technology platform</td> <td>Other:</td> </tr> </table>	Metabolic diseases	inflammation/ immunity	chronic viral infectious diseases	CNS	Renal diseases	Dermatological diseases	Technology platform	Other:
Metabolic diseases	inflammation/ immunity								
chronic viral infectious diseases	CNS								
Renal diseases	Dermatological diseases								
Technology platform	Other:								
Management Team and Scientific Board:									

Technology description* <i>(200 words max)</i>	
Key partnership objectives* <i>(200 words max)</i>	
Current partnerships and/or alliances <i>(200 words max)</i>	
Status and protection of intellectual property	
Development status and next steps* <i>(200 words or fewer)</i>	

Ownership	
Capital raised to date, and investors	
Amount of capital sought, and milestones to be achieved on that capital	

If applicable